An Open-label Study to Evaluate the Single-dose Pharmacokinetics and Safety of Ceftobiprole in Neonate and Infant Subjects Aged up to 3 Months Undergoing Treatment With Systemic Antibiotics
Phase of Trial: Phase I
Latest Information Update: 03 Dec 2017
At a glance
- Drugs Ceftobiprole medocaril (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Basilea Pharmaceutica
- 12 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2018.
- 12 May 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Dec 2018.
- 30 Mar 2016 Planned End Date changed from 1 Jun 2016 to 1 Jun 2017 as reported by ClinicalTrials.gov.